Novo Nordisk partners with AWS to accelerate AI-driven drug discovery
Reuters2026/08/10 12:02- Novo Nordisk struck a strategic partnership with AWS to accelerate drug discovery using agentic AI and cloud technology.
- A new co-innovation hub in London will embed AWS engineers and scientists with Novo Nordisk R&D to shorten timelines from target to first human dose.
- AWS becomes Novo Nordisk’s preferred cloud provider and strategic AI partner as the drugmaker modernizes its technology infrastructure.
- The companies cited early gains, including shorter clinical documentation time and AI tools rolled out to more than 25,000 employees.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Goldman Sachs: AI storage chip demand is underestimated, South Korean stock market still has 80% upside potential
Goldman Sachs Asia-Pacific Chief Equity Strategist Timothy Moe maintains a KOSPI target of 12,000 points, implying an almost 80% increase from the current level. He points out that the market is systematically underestimating the sustainability of the AI storage chip profit cycle. Capital expenditures by US tech giants may exceed $1.2 trillion next year, and the chip shortage triggered by data center expansion will further intensify in 2027. The current KOSPI is trading at only 5.3 times expected earnings, about half of its historical average.
Norwegian sovereign wealth fund may cut $80 billion US Treasury holdings; high-rated mortgage securities expected to become new favorites
Norway's sovereign wealth fund, with a scale of $2.3 trillions, has recommended reducing government bond holdings and reallocating funds towards higher-yielding fixed income assets.
Crypto prices
More
